Evidence Series Resource Hub

Home - Reagents

Evidence Series Resource Hub

Evidence Series | Resource Hub

  • Brochures
  • Flyers
  • Videos
  • Blogs
  • Scientific Posters
  • Whitepapers

Evidence

Evidence Investigator

Evidence MultiSTAT

Evidence+

Evidence Evolution

Biochip Technology Explained

Evidence series Overview

Discover more about the Evidence series

 

Cytokines Flyer

DIKI Renal Flyer

A4 Renal Flyer

AKI Covid-19 Flyer

Evidence Investigator - Molecular Diagnostic Testing

Evidence MultiSTAT Demonstration

Evidence Evolution - World's Most Advanced Immunoanalyser

Evidence Investigator - Myco 9 Array, Step By Step

DEVELOPMENT OF A BIOCHIP ARRAY FOR THE SIMULTANEOUS DETECTION OF CANCER BIOMARKERS ON THE RANDOM ACCESS, FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER

DEVELOPMENT OF A DUPLEX BIOCHIP ASSAY FOR THE SIMULTANEOUS DETECTION OF ANTI-THYROGLOBULIN AND ANTI-THYROID PEROXIDASE ANTIBODIES ON THE FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER

DEVELOPMENT OF NEW BIOCHIP ARRAYS FOR THE DETERMINATION OF BIOMARKERS RELATED TO ACUTE KIDNEY INJURY APPLIED TO THE EVIDENCE INVESTIGATOR ANALYSER

DEVELOPMENT OF A NEW BIOCHIP BASED IMMUNOASSAY FOR THE DETECTION OF PARATHYROID HORMONE APPLIED TO THE EVIDENCE EVOLUTION ANALYSER

DEVELOPMENT OF A HIGHLY MULTIPLEXED MOLECULAR ASSAY FOR DETECTION OF INFECTION IN CF AIRWAYS

Repeatability and within-laboratory precision were assessed (n=80): Assay Repeatability Within-laboratory precision CV (%) CV (%) VCAM-1 4.5 6.8 ICAM-1 5.6 8.8 ESEL 12.8 16.6 PSEL 3.5 4.7 LSEL 5.7 8.2 17.096, 097.105RDRT DEVELOPMENT OF A BIOCHIP ARRAY FOR THE DETECTION OF ADHESION MOLECULES ON THE NEW RANDOM ACCESS FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER

DEVELOPMENT OF A NEW BIOCHIP BASED IMMUNOASSAY UNAFFECTED BY DHEA-S INTERFERENCE FOR THE ACCURATE MEASUREMENT OF SERUM PROGESTERONE

DEVELOPMENT OF A BIOCHIP ARRAY FOR THE RAPID, SIMULTANEOUS DETECTION OF PEPSINOGEN I, PEPSINOGEN II AND GASTRIN 17, ON THE NEW RANDOM ACCESS, FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER

CLINICAL EVALUATION OF A RAPID FULLY-AUTOMATED MULTIPLEX BIOCHIP ARRAY FOR STROKE DIAGNOSIS

DEVELOPMENT OF A NEW BIOCHIP ARRAY APPLIED TO THE NEW RANDOM ACCESS FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER FOR THE SIMULTANEOUS MEASUREMENT OF TSH, FREE T4 AND FREE T3

DEVELOPMENT OF A NEW BIOCHIP BASED IMMUNOASSAY FOR THE MEASUREMENT OF TOTAL 25-HYDROXYVITAMIN D IN SERUM AND THE ACCURATE CLASSIFICATION OF VITAMIN D STATUS

DEVELOPMENT OF A BIOCHIP ASSAY FOR THE DETECTION OF THYROXINE-BINDING GLOBULIN (TBG) ON THE NEW RANDOM ACCESS FULLY AUTOMATED EVIDENCE EVOLUTION ANALYSER

GENETIC DIAGNOSIS OF MONOGENIC OR POLYGENIC FAMILIAL HYPERCHOLESTEROLEMIA IN NORTHERN IRELAND: EVALUATION OF THE RANDOX FH ARRAYS IN COMBINATION WITH THE RANDOX 6SNP POLYGENIC HYPERCHOLESTEROLEMIA ARRAY

DEVELOPMENT OF A BIOCHIP ARRAY FOR THE SIMULTANEOUS MEASUREMENT OF DISTINCT FATTY ACID-BINDING PROTEINS (FABPs)

DEVELOPMENT OF A NEW ENZYME-LINKED IMMUNOSORBENT ASSAY KIT TO DETECT NGAL IN HUMAN SERUM AND ITS APPLICATION TO CHRONIC KIDNEY DISEASE

SCREENING AND SELECTION OF ANTIBODIES FOR THE DETECTION OF MIP-1 ALPHA AND ITS APPLICATION TO THE STUDY OF CHRONIC KIDNEY DISEASE

DEVELOPMENT OF A 4-PLEX BIOCHIP ARRAY FOR THE EARLY DETECTION OF CHRONIC KIDNEY DISEASE

DEVELOPMENT OF A THIRD GENERATION TSH ASSAY ON THE NEW RANDOM ACCESS EVIDENCE EVOLUTION FULLY AUTOMATED BIOCHIP ANALYSER

APPLICATION OF THE NEW RANDOM ACCESS, FULLY AUTOMATED BIOCHIP ANALYSER EVIDENCE EVOLUTION TO SIMULTANEOUSLY MEASURE ANALYTES RELATED TO ENDOCRINE FUNCTION

SARS-CoV-2 Vascular & Multi-System Dysfunction


Why does Randox sponsor Equine Sports events?

Why does Randox sponsor Equine Sports?

16 March 2021: Why does Randox sponsor Equine Sports?

Some may be wondering, why is a healthcare company so invested in the equine industry? Why would they sponsor the world’s most famous steeplechase?

It’s a labour of love… Peter FitzGerald’s fond attachment to the equestrian world, together with almost 40 years’ experience in the in vitro diagnostics industry, was the perfect match.

Clinical diagnostics is at the heart of Randox and our experience and expertise has paved the way for the development of innovative and accurate diagnostic products for Equine Health.

You could say ‘it runs in our blood.’

With 70% of all medical decisions based on the analysis of blood, Randox are set to release the VeraSTAT-V, a stable-side Equine Serum Amyloid A test device designed to detect levels of inflammation in horse blood in a matter of minutes.

The ability to quickly detect and monitor your horse’s health, at the stable side, brings huge benefits to both horse and owner. Early detection of inflammatory states means treatment plans can start sooner, recovery periods are shorter, and the horse can return to work healthy much earlier.

When performance is key, monitoring inflammation is vital.

Whether it’s detecting inflammation related to joint injury, or screening for infection before or after transport, competition or surgery, the VeraSTAT-V is a valuable means to monitor Equine Health.

At Randox, we have enjoyed a long-standing partnership with the Jockey Club and will continue to deliver innovative diagnostics solutions to the Equine Industry for the years ahead.

Keep an eye out for the release of the VeraSTAT-V – coming soon.

For all Equine SAA inquiries, please email marketing@randox.com or visit www.randox.com/veraSTAT for more information.

QUALITY CONTROL

REAGENTS

RX SERIES


Beckman Coulter AU

Randox Acetaminophen Reagent

We develop a range of applications for the Beckman Coulter AU Series (400 / 480 / 600 / 640 / 680 / 2700 / 5400 / 5800 / DxC700AU) analysers so that laboratories worldwide can enjoy the benefits of freedom of choice from an independent manufacturer, Randox Laboratories. We have 89 reagents available for the Beckman Coulter AU (400 / 480 / 600 / 640 / 680 / 2700 / 5400 / 5800 / DxC700AU) analysers, and are always developing more. If you don’t see the application you are looking for, please contact us to request an application.

All kits are produced to international standard and have ISO 13485 accreditation.

Existing customers can access IFU’s through Powerline.


Cardiology Reagents Panel

Cardiology Reagents

Randox Cardiology Reagents Panel

Randox is a leading provider of diagnostic reagents for the assessment of cardiovascular disease risk. Our extensive menu of cardiac biomarkers within the cardiology reagents panel include:

Routine lipid tests such as Homocysteine, hsCRP, Apo A-I, Apo A-II, Apo B and Lp(a). Our cardiology reagents offer superior performance and are available for use on a wide range of clinical chemistry analysers.

Unique assays for cardiac risk assessment include sdLDL Cholesterol, Apo C-II, Apo C-III, Apo E and Adiponectin. In addition, our range of unique cardiology reagents includes H-FABP for the early detection of myocardial infarction.

Benefits of Randox Cardiology Assays

  • Liquid ready-to-use reagents for convenience; we also offer lyophilised reagents for CK-MB, HDL Cholesterol and Triglycerides
  • Wide measuring ranges for accurate detection of abnormal levels
  • Strong correlation to reference methods for trusted results
  • Applications available for a wide range of clinical chemistry analysers
  • Unique reagents enable impeccable patient care with an expanded profile for cardiac risk assessment

To order your cardiology kits visit our online store or contact us using our short enquiry form to request more information on specific cardiology reagents.

Cardiovascular disease

Cardiovascular disease refers to a variety of diseases which cause reduced blood flow to the heart, brain or body and is alos a leading cause of death. Such diseases include those affecting the blood vessels supplying the heart (coronary heart disease), brain (cerebrovascular disease), and arms and legs (peripheral arterial disease). Restrictions to blood flow can be a result of a blood clot (thrombosis), or narrowed arteries caused by a build-up of fatty deposits (atherosclerosis). The effects of this can lead to stroke or heart attack.

Risk Assessment

  • CK-MB useful in patients with chest pain; Creatine Kinase is an enzyme produced in many different types of cells, of which high levels indicate muscle trauma or damage.
  • Myoglobin, a small protein which leaks out of muscle cells after injury, is also considered a biomarker for the detection of Myocardinal Infraction.
  • Routine lipid tests to determine the patient’s cholesterol and triglyceride levels – HDL Cholesterol, LDL Cholesterol, Total Cholesterol and Triglycerides
  • Independent risk assessment tests such as sdLDL Cholesterol and Lipoprotein(a) to determine any genetic factors which may increase their risk of CVD. Please note, this is necessary even for patients who have good cholesterol levels
  • Secondary tests, such as High Sensitivity CRP, in addition to risk assessment markers and lipid evaluation – secondary tests are important in predicting future cardiac events of individuals with no previous history of CVD and those deemed healthy as a result of primary tests; approximately half of all heart attacks occur in patients classified as low risk. In addition, they can also be used to evaluate the risk of a recurrent cardiac event
  • Speciality tests include
    • Homocysteine – elevated levels of homocysteine have been linked to various disease states including CVD. Extremely high levels are found in patients with homocystinuria, of which many suffer from early arteriosclerosis.

Beta-2 Microglobulin Reagent

Reagent | Beta 2 Microglobulin

Key Benefits of the Beta-2 Microglobulin reagent

Wide measuring range

The healthy range of beta-2 microglobulin is 0.9 – 3.0 mg/l. The Randox Beta-2 Microglobulin reagent can comfortably detect levels outside of this range with a measuring range of 0.476 – 20.9 mg/l.

Excellent stability

Stable until expiry date when stored at +2 to +8⁰C

Liquid ready-to-use reagents

The Randox Beta-2 Microglobulin reagent comes in a liquid format which is more convenient as the reagent does not need to be reconstituted which aids in reducing the risk of errors occurring

Other features of the Beta-2 Microglobulin reagent

  • Immunoturbidimetric
  • Liquid ready-to-use reagents
  • Stable to expiry when stored at +2 to +8⁰C
  • Measuring range 0.476 – 20.9 mg/l
Cat NoSize    
BM3887R1 2 x 11ml
R2 2 x 4.3ml
EnquireKit Insert RequestMSDSBuy Online

Instrument Specific Applications (ISA’s) are available for a wide range of biochemistry analysers.  Contact us to enquire about your specific analyser.

What is the Beta-2 Microglobulin assay used for?

What is beta-2 microglobulin?

Located on the surface of most cells, especially nucleated cells, are large surface proteins called Class I antigens which are made up of a heavy chain and a light chain. The heavy chain is produced by multiple genes and the light chain is chemically bound to it.  This light chain is the beta-2 microglobulin.  Class I antigens are mostly expressed on lymphoid cells and expressed less on the lungs, kidney and liver and are sparsely expressed on skeletal muscle and the brain.  Beta-2 microglobulin is shed by the cells which becomes detectable in the bloodstream under normal conditions.

What is the beta-2 microglobulin assay used for?

Elevated concentration levels of beta-2 microglobulin is attributed to diseases with a high cell turnover.  It is a powerful prognosis factor for multiple myeloma, a type of bone marrow cancer.  It is also used to detect chronic lymphocytic leukemia and some types of lymphomas. For more information on tumor markers, please click here [external link].

Low concentration levels of beta-2 microglobulin in serum and high concentration levels is urine is attributed to renal tubular disease. This is particularly important during the onset on diabetes as the kidneys grow larger and the glomerular filtration rate (GFR) becomes supranormal which are risk factors for the development of diabetic nephropathy in later life. For more information on renal function in diabetic disease model, please click here [external link].

The Randox Beta-2 Microglobulin assay is used as a white blood cell tumor marker as well as a biomarker for renal disease.

Diabetes Panel

For more information or to visit more reagents within the diabetes panel, please click here


Lipid Testing Panel

Lipid Panel Testing Panel | Reagents

Cardiovascular disease (CVD) caused by atherosclerosis (arteriosclerosis) is the leading cause of morbidity and mortality in Western countries1. Atherosclerosis involves the hardening and narrowing of vessels in the systemic system. This process originates from the build-up of fatty deposits through a process known as atherogenesis. If the build-up increases, plaque rupturing may occur which may lead to myocardial infarction2.

The mission of the National Lipid Association (NLA) “is to enhance the practice of lipid management in clinical medicine”.  NLA advocate advancing the current lipid testing profile. The current lipid panel consists of testing LDL cholesterol, HDL cholesterol and triglycerides, which only detects approximately 20% of all atherosclerotic cardiovascular disease (ASCVD) patients.  Advanced lipid testing is recommended to optimise patient treatment3.

Current Challenges

icons +7

75% of circulatory risk factors are preventable4

Lipids-01

6 million people in the UK suffer from narrowing of the heart arteries5

icons +14

1 in 4 deaths in the US is attributed to heart disease6

How Randox can help with the current challenges

 

 

Randox is a leading provider of diagnostic reagents for lipid testing.  In addition to routine tests, Randox offer a range of niche and superior performance assays including: sdLDL-C, Lp(a) and HDL3-C.

 

 

  • Randox Lipid Reagents
  • Benefits of Randox Lipid Reagents
  • Risk Assessment using Randox lipid reagents
icons ++

Liquid ready-to-use assays
The Randox lipid assays are available in a liquid ready-to-use format for convenience and ease of use. (The Triglycerides kit is also available in a lyophilised format).

icons ++6

Wide measuring ranges
The Randox lipid assays can comfortably detect levels outside of the healthy range for the accurate detection of abnormal levels, offering peace of mind in patient samples.

icons ++3

Excellent correlation with standard methods
The Randox lipid assays display excellent correlations when compared against standard methods, offering trust and confidence in results.

icons ++4

Applications are available
Applications are available detailing instrument-specific settings for the convenient use of the Randox lipid assays on a wide range of clinical chemistry analysers.

As the current lipid panel consists of testing LDL cholesterol, HDL cholesterol and triglycerides, which only detects approximately 20% of all coronary artery disease (CAD) patients, advanced lipid testing is recommended to optimise patient treatment. The Randox lipid profile encompasses niche and superior performance assays for the detection of conventional risk factors, as well as emerging biomarkers associated with further risk.

Lipids-06

Apolipoprotein C-III (Apo C-III)
A niche product from Randox, Apo C-III deficiency has shown to increase the rate of triglyceride clearance from plasma by up to 7 fold. Apo C-III levels have been reported higher in several conditions such as type 2 diabetes, hyperbilirubinemia and decreased thyroid function.

Lipids-04

Apolipoprotein E (Apo E)
A niche product from Randox, Apo E has been found to have an association with neurodegenerative conditions such as Alzheimer’s Disease and Multiple Sclerosis. A deficiency in Apo E gives rise to high levels of serum cholesterol and triglycerides, leading to premature atherosclerosis

Lipids-05

HDL3 Cholesterol (HDL3-C)
A niche product from Randox, HDL3-C, a subclass of HDL-C, has an inverse correlation with CVD risk. Several clinical studies indicate that measuring these HDL-C subclasses better reflects primary and secondary CHD risk than measurement of total HDL-C, making it a significant independent biomarker for better risk profiling when used together with other risk markers.

Lipids-07

Lipoprotein (a) (Lp(a))
A unique product from Randox, Lp(a) has proven to have a causal role in the premature development of atherosclerosis and CVD as elevated Lp(a) levels associate robustly and specifically with increased CVD risk. The Randox Lp(a) assay is one of the only methodologies on the market that detects the non-variable part of the Lp(a) molecule and therefore suffers minimal size related bias.

sdLDl-C

Small-dense LDL Cholesterol (sdLDL-C)
A niche product from Randox, sdLDL-C, a subtype of LDL cholesterol, can more readily permeate the inner arterial wall. Research indicates that individuals with a predominance of sdLDL-C have a 3-fold increased risk of myocardial infarction.

Want to know more?

Contact us or visit our download our Cardiology & Lipid Testing brochure to learn more.




  • Circulatory Health Problems
  • Tips to improve circulatory health

Cardiovascular disease (CVD) refers to disease of the heart or blood vessels. Heart disease encompasses a number of diseases that affect the heart. In contrast, vascular disease encompasses a number of diseases that affect the blood vessels. Circulatory health problems are the result of vascular disease. Developing problems within the vascular system can go undetermined and in some patients the problem may only become apparent when they experience a heart attack or stroke 7.

Lipids-01

Atherogenesis and Atherosclerosis

Atherogenesis is a circulatory disease whereby atheromas are formed (plaque build-up) within the artery.  Plaque is a combination of cholesterol, fat, calcium, lipids and other substances within the blood stream.  As time progresses, the plaque hardens, narrowing the arteries.  This is known as atherosclerosis. Consequently, blood flow through the narrowed artery is reduced, limiting the supply of blood to vital organs and bodily tissues.  As atherogenesis can affect any artery within the body, different diseases may develop based on the artery that is affected.  Such diseases include: coronary heart/artery disease, carotid artery disease, peripheral artery disease and chronic kidney disease8.

Lipids-02

Plaque Rupture

As atherogenesis and atherosclerosis causes plaque to build up and harden within the arteries precipitating thrombi, blood flow to the heart, brain, or the lower extremities is obstructed (depending on the artery affected).  This can further develop into coronary heart/artery disease (heart), ischemic stroke (brain) or peripheral vascular disease (lower extremities).  However, the most common and most discussed of these manifestations is coronary heart/artery disease9.  These manifestations occur when the plaque ruptures.  The risk of the plaque rupturing is determined by the type of plaque (composition) rather than the size of the plaque (volume) as only plaques that are rich in soft extracellular lipids are rupture-prone (vulnerable).  Whilst most plaque ruptures are small causing an acute coronary event, the actual vulnerability of the plaque may change over time.  Luckily, the vulnerable plaque components are most likely to regress with treatment10.

icons +7

Myocardial Infarction

The processes of atherogenesis, atherosclerosis and plaque rupturing, if left undetected can a myocardial infarction (MI) or “heart attack” if the plaque build-up has occurred in the coronary artery11. MI occurs when the blood supply to heart is completely blocked by the formation of a clot or a blockage due to a loose piece of atheroma (plaque rupturing). If the blood supply to the heart is blocked the cells in the heart begin to die due to the lack of oxygen, causing chest pain (angina). The extent of the blockage and the amount of heart muscle affected will determine whether this malfunction will affect the hearts ability to pump blood12. The signs of atherogenesis, atherosclerosis and plaque rupturing can be subtle, and most heart attack victims may only feel symptoms in the days leading up to the attack. For 80% of people, the first sign of a heart attack is angina. Other symptoms to be aware of are shortness of breath, anxiety, sweating, light-headedness and temporary changes in vision 11.

icons +18

Exercise

Regular exercise has a major effect on your circulation and cardiovascular health. Moderate levels of exercise can increase blood flow and reduce the risk of poor circulatory health conditions such as atherosclerosis. Exercise promotes good circulation as it strengthens the heart muscles, lowing the resting heart rate and preventing the build-up of plaque in the arteries. It is important for those with current circulation problems to be vigilant while exercising to ensure they are not over exerting themselves13.

icons +19

Know your healthy fats

Diet changes are important for improving circulatory health. Eating a variety of foods such as lean meats, vegetables, fruits, legumes and whole grains will aid in lowering lipid levels and keep them low. It is recommended that more unsaturated fats are consumed in comparison to saturated fats, as saturated fats raise sdLDL-C levels which can lead to an increased risk of atherosclerosis. On the other hand, unsaturated fats such as monounsaturated or polyunsaturated fats may increase HDL levels and are known as being ‘heart-healthy’. It is recommended to find healthier alternatives for certain foods such as butter and oil14.

smoking icon

Stop Smoking

Smoking can cause circulatory problems in several ways. Most notably it can cause the carotid arteries (arteries which supply oxygen to the brain) to become filled with plaque. Also, smoking can cause PAD by reducing adequate blood supply to the limbs which can lead to leg pain and possibly amputation. Quitting smoking has been proven to have positive effects on circulation: just 20 minutes after a cigarette, blood pressure decreases and oxygen levels return to normal. Within 24 hours, the chance of a heart attack will have already decreased and after 48 hours, nerve endings deeded by the habit are expected to regenerate, with sense of taste and smell improving also. A year after quitting, the risk of coronary heart disease (CHD) will be halved. After 15 years, a quitter’s risk of CHD is now similar to that of a person who has never smoked14.

Want to know more?

Contact us or visit our download our Cardiology & Lipid Testing brochure to learn more.




Related Products

Cardiology Testing Panel

Featured Reagent Home

Reagents Resource Hub

  • References

    [1] Burnett, John R. Lipids, Lipoproteins, Atherosclerosis and Cardiovascular Disease. National Center for Biotechnology Information (NCBI). [Online] Clin Biochem Rev., 25 February 2004. [Cited: 3 December 2018.] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1853363/.

    [2] Zimmermaann, Kim Ann. Circulatory Systenm: Facts, Function & Diseases. Live Science. [Online] 16 March 2018. [Cited: 3 December 2018.] https://www.livescience.com/22486-circulatory-system.html.

    [3] National Lipid Association. National Lipid Association Releases Updated Recommendations on the Use of PCSK9 Inhibitors at the 15th Annual Scientific Session. [Online] no date. [Cited: 3 December 2018.] https://www.lipid.org/nla/national-lipid-association-releases-updated-recommendations-use-pcsk9-inhibitors-15th-annual.

    [4] World Heart Federation. Driving Sustainable Action for Circulatory Health: Whitepaper for Circulatory Health. [Online] Global Coarlition for Circulatory Health, no date. [Cited: 30 November 2018.] https://www.world-heart-federation.org/wp-content/uploads/2018/11/White-Paper-for-Circulatory-Health.pdf.

    [5] British Heart Foundation. Research into atherosclerosis: 4 scientists talk about their work. [Online] no date. [Cited: 30 November 2018.] https://www.bhf.org.uk/informationsupport/heart-matters-magazine/research/atherosclerosis..

    [6] Centers for Disease Control and Prevention. Heart Disease Facts. [Online] 28 November 2017. [Cited: 4 December 2018.] https://www.cdc.gov/heartdisease/facts.htm.

    [7] Cardiovascular Disease. NHS. [Online] NHS UK, September 15, 2018. [Cited: November 30, 2018.] https://www.nhs.uk/conditions/cardiovascular-disease/

    [8] National Heart, Lunch, and Blood Institute. Atherosclerosis. [Online] no date. [Cited: 28 November 2018.] https://www.nhlbi.nih.gov/health-topics/atherosclerosis.

    [9] Fog Bentzon, Jacob, et al. Mechanisms of Plaque Formation and Rupture. Circulation Research. [Online] 6 June 2014. [Cited: 29 November 2018.] https://www.ahajournals.org/doi/abs/10.1161/circresaha.114.302721.

    [10] Falk, E. Why do plaques rupture? National Center for Biotechnology Information. [Online] Circulation, December 1992. [Cited: 29 November 2018.] https://www.ncbi.nlm.nih.gov/pubmed/1424049.

    [11] MedBroadcast. Heart Attack (Myocardial Infarction, MI). [Online] no date. [Cited: 30 November 2018.] https://medbroadcast.com/condition/getcondition/heart-attack.

    [12] Harvard Health Publications. Heart Attack (Myocardial Infarction. [Online] 10 September 2018. [Cited: 30 November 2018.] https://www.drugs.com/health-guide/heart-attack-myocardial-infarction.html.

    [13] Bergeson Becco, Laine. How Exercise Affects Circulation (and Vice Versa). Experience Life. [Online] June 2017. [Cited: 4 December 2018.] https://experiencelife.com/article/how-exercise-affects-circulation-and-vice-versa/.

    [14] Mayo Clinic. Top 5 lifestykle changes to improve your cholesterol. [Online] 11 August 2018. [Cited: 4 December 2018.] https://www.mayoclinic.org/diseases-conditions/high-blood-cholesterol/in-depth/reduce-cholesterol/art-20045935.


Bile Acids Reagent

Bile Acids Reagents

Key Benefits of the Bile Acids reagent

Excellent linearity

The Randox Bile Acids method is linear up to a concentration of 150 µmol/l

Exceptional correlation with standard methods

The Randox methodology was compared against other commercially available methods and the Randox Bile Acids assay showed a correlation coefficient of 0.99

Liquid ready-to-use reagent

The Randox Bile Acids reagent comes in a two shot ready-to-use liquid format which is more convenient as the reagent does not need to be reconstituted which aids in reducing the risk of errors occurring

Other features of the Randox Bile Acids reagent

  • Colorimetric method
  • Liquid and lyophilised reagents available
  • Stable to expiry when stored at +2 to +8°C
  • Measuring range 1.47 – 150 µmol/l
  • Protocols are available for a range of analysers
Cat NoSize    
BI2672R1 10 x 10ml
R2 1 x 30ml
EnquireKit Insert RequestMSDSBuy Online
BI3863 (5th)R1 2 x 18ml
R2 2 x 8ml
EnquireKit Insert RequestMSDSBuy Online

Instrument Specific Applications (ISA’s) are available for a wide range of biochemistry analysers.  Contact us to enquire about your specific analyser.

What is the Bile Acids assay used for?

  • Clinical Significance
  • Biological Significance
  • Inadequacies of traditional bile acid assays

Liver Function

Measuring total bile acid (TBA) levels may prove useful for the detection of liver diseases such as viral hepatitis, mild liver injury through drug use and for further evaluation of patients with chronic hepatitis who were previously treated successfully. TBA levels may rise up to 100 times the normal concentration in patients with liver disease due to impairment of hepatic synthesis and extraction of bile acids. Measurement of TBA in serum can be used in the diagnosis and prognosis of liver diseases and may detect some forms of liver disease earlier than standard liver markers due to the correlation of TBA with liver function, rather than liver damage.

Bile Acid Deficiency

TBA deficiency is caused by a genetic error in one of the 17 enzymes that produce bile acids. Deficiency can lead to liver failure and even death in infants, therefore early detection is vital. People with TBA deficiency may exhibit symptoms, including:

• Vitamin deficiencies, specifically of fat-soluble vitamins such as A, D, E, and K
• Jaundice
• Stunted or abnormal growth
• Diarrhoea
• Loss of liver function
• Liver failure

Intrahepatic Cholestasis of Pregnancy

Intrahepatic cholestasis of pregnancy (ICP) or obstetric cholestasis is a pregnancy-specific liver disorder. It can be indicated by pruritus, jaundice, elevated TBA levels and/or serum transaminases and usually affects women during the second and third trimester of pregnancy. ICP is a condition that restricts the flow of bile through the gallbladder resulting in a build-up of TBA in the liver. Due to the build-up, Bile Acids leak into the bloodstream where they are detected at concerning levels. It is an extremely serious complication of pregnancy that can lead to the increased risk of premature birth or even stillbirth as such it is vital that women with the condition are monitored carefully.

According to several reports TBA levels in ICP can reach as high as 100 times the upper limit of a normal pregnancy. It has been reported that a doubling in maternal serum TBA levels, results in a 200% increased risk of stillbirth. Additionally, bile acids can affect the foetal cardiovascular system as it has been found that there are often cardiac rhythm disturbances in the foetus due to the elevated TBA in circulation.

There are several risk factors associated with ICP such as family history, use of oral contraceptives, assisted reproduction techniques and multiple gestation. Genetic influence accounts for approximately 15% of ICP cases. Dietary selenium is a contributing environmental factor as serum selenium levels often decrease throughout pregnancy. Further to this, incidences of ICP rise in the winter months and are most likely due to the fact selenium levels are naturally less during these months. In healthy pregnancies, there is very little increase in TBA levels although a slight increase is likely to be seen in the third trimester.

Measurement of TBA in serum is thought to be the most suitable method of diagnosing and monitoring ICP.

Bile acids are water-soluble and amphipathic end products of cholesterol metabolism formed in the liver. Bile is stored in the gall bladder and released into the intestine when food is consumed. The fundamental role of bile acids is to aid in the digestion and absorption of fats and fat-soluble vitamins in the small intestine. In doing so, bile acids have five physiological functions within the body as shown below:

Determining the cause and extent of liver damage is important in guiding treatment decisions and preventing disease progression. Standard liver function tests include; ALT, AST, ALP, GGT and Bilirubin. The measurement of TBA is most beneficial in conjunction with these standard liver tests and offers unrivalled sensitivity allowing identification of early stage liver dysfunction.

There are several commercial methods available for the detection and measurement of TBA in serum. Traditional TBA tests based on the enzymatic method use nitrotetrazolium blue (NBT) to form a formazan dye. The reaction is measured at 546nm and the intensity of the colour is proportional to the concentration of bile acids.

Newer methods such as the enzyme cycling method or fifth generation methods offer many advantages including greater sensitivity, liquid reagents, small sample volumes and reduced instrument contamination from formazan dye. Additionally, the fifth generation assay does not suffer from interference from lipaemic or haemolytic samples. Both lipaemia and haemolysis are common in new-borns and pregnant women.

Enzyme cycling methods offer superior analytical performance, two reactions are combined. In the first reaction, bile acids are oxidised by 3-α hydroxysteroid dehydrogenase with the subsequent reduction of Thio-NAD to Thio-NADH. In the second reaction, the oxidised bile acids are reduced by the same enzyme with the subsequent oxidation of NADH to NAD. The rate of formation of Thio-NADH is determined by measuring the specific absorbance change at 405nm. Enzyme cycling means multiple Thio-NAD molecules are generated from each bile acid molecule giving rise to a much larger absorbance change and signal amplification, increasing the sensitivity of the assay.

The assay principle is demonstrated in the diagram below:

The Randox fifth generation assay utilises the advanced enzyme cycling method which displays outstanding sensitivity and precision compared to traditional enzymatic based tests. The assay shows excellent linearity of up to 188 µmol/l with the normal upper range of TBA in a fasting serum sample being at 10 µmol/l. The liquid ready-to-use reagent is available along with complementary controls and calibrators for a complete testing package.

Clinical Chemistry Panel

For more information or to visit more reagents within the clinical chemistry panel, please click here

Veterinary Panel

For more information or to visit more Reagents within the veterinary panel, please click here


Abbott Alinity

Randox Acetaminophen Reagent

We develop a range of applications for the Abbott Alinity analyser so that laboratories worldwide can enjoy the benefits of freedom of choice from an independent manufacturer, Randox Laboratories. We have 17 reagents available for the Abbott Alinity, and are always developing more. If you don’t see the application you are looking for, please contact us to request an application.

All kits are produced to international standard and have ISO 13485 accreditation.

Existing customers can access IFU’s through Powerline.


Apolipoprotein A-II

Reagent | Apolipoprotein A-II

Key Benefits

Wide measuring range

With a measuring range of 6.75-61.1 mg/dl, it will comfortably detect levels outside of the healthy range of 25.1-34.5mg/dl

Excellent stability

Stable to expiry when stored at 2-8°C

Liquid ready-to-use reagents

The Randox Apolipoprotein A-II reagent comes in a liquid format which is more convenient, and can also help reduce the risk of errors occurring

Other features

  • Immunoturbidimetric
  • Liquid ready-to-use reagents
  • Stable to expiry when stored at 2-8°C
  • Measuring range 6.75-61.1 mg/dl
Cat NoSize    
LP3867R1 2 x 11ml
R2 2 x 5ml
EnquireKit Insert RequestMSDSBuy Online

Instrument Specific Applications (ISA’s) are available for a wide range of biochemistry analysers.  Contact us to enquire about your specific analyser.

What is Apolipoprotein A-II assay used for?

Apolipoproteins are proteins on the surface of the lipoprotein complex that bind to specific enzymes or transport proteins on the cell membranes. This directs the lipoprotein to the proper site of metabolism. APO A-II is mainly created in the liver and modulates lipoprotein lipase and hepatic triglyceride lipase. It also acts as a co-factor for Lecithin Cholesterol Acyltransferase which is involved in lipoprotein processing.

Apolipoprotein A-II is a major constituent of High Density Lipoprotein (HDL) particles and plays an important role in the reverse cholesterol transport and lipid metabolism. The APO A-II test can be used as an aid in assessing the risk of CVD.


5th Generation Bile Acids Assay

5th Generation Bile Acids

A Superior Method for Intrahepatic Cholestasis of Pregnancy (ICP) Testing

Benefits of the Randox 5th Generation Bile Acids Assay

Superior Performance

Superior methodology

Utilising the advanced enzyme cycling method, the Randox 5th generation bile acids assay displayed outstanding sensitivity and precision when compared to the traditional enzymatic based tests.

 

Measuring range

Excellent measuring range

The Randox 5th generation bile acids assay has a measuring range of 2.16 – 238µmol/l for the comfortable detection of clinically important results.

 

Correlation

Exceptional correlation

A correlation coefficient of r=0.99 was displayed when the Randox method was compared against other commercially available methods.

 

Liquid ready-to-use

Liquid ready-to-use

The Randox 5th generation bile acids is available in a liquid ready-to-use format for convenience and ease-of-use.

 

Calibrator & Controls

Calibrator and controls available

Calibrator and controls are available offering a complete testing package.

 

Applications available

Applications available detailing instrument-specific settings for the convenient use of the Randox 5th generation bile acids assay on a variety of clinical chemistry analysers.

 

A 4th generation method for bile acids testing is also available which offers an excellent linearity up to 150µmol/l. Applications available detailing instrument-specific settings for the convenient use of the Randox 4th generation bile acids assay on a variety of clinical chemistry analysers.

 

  • Ordering Information
  • INTRAHEPATIC CHOLESTASIS OF PREGNANCY
  • TRADITIONAL DIAGNOSTIC TESTING
  • THE FIFTH GENERATION TEST
Cat NoSize    
BI7982R1 6 x 50ml
R2 6 x 18ml
EnquireKit Insert RequestMSDSBuy Online
BI3863R1 2 x 18ml
R2 2 x 8ml
EnquireKit Insert RequestMSDSBuy Online

Instrument Specific Applications (ISA’s) are available for a wide range of biochemistry analysers.  Contact us to enquire about your specific analyser.

Intrahepatic cholestasis of pregnancy (ICP) or obstetric cholestasis is a pregnancy-specific liver disorder. ICP, characterised by maternal pruritus in the absence of a rash and increased total bile acids (TBA) levels, is a severe form, yet reversible, cholestasis commonly occurring in the second and third trimester of pregnancy. Diagnostic and therapeutic guidelines are lacking for ICP which is of concern as ICP can have significant foetal risks 1, 2.

ICP restricts the flow of bile through the gallbladder causing bile acids to build-up in the liver 2. Due to the build-up, bile acids leak into the bloodstream where they are detected at concerning levels.  It has been documented that TBA levels in ICP can reach as high as 100 times the upper limit of a normal pregnancy. Moreover, a doubling in maternal serum TBA levels, results in a 200% increased risk of stillbirth. Additionally, elevated serum bile acids can affect the foetal cardiovascular system causing issues such as cardiac rhythm disturbances 3.

Whilst other liver function tests exist, including: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT) and bilirubin; TBA testing is thought to be the most beneficial method for the diagnosis and monitoring ICP. Moreover, TBA measurements are believed to be the most beneficial when tested in conjunction with standard liver tests, offering unrivalled sensitivity enabling the identification of early stage hepatic dysfunction 3.

The enzyme cycling method enables signal amplification through cycled regeneration reactions. In the presence of Thio-NAD, the enzyme 3-α hydroxysteroid dehydrogenase (3-α HSD) converts bile acids to 3-keto steroids and Thio-NADH (Fig. 1).  The reaction is reversible and 3-α HSD can convert 3-keto steroids and Thio-NADH to bile acids and Thio-NAD.  In the presence of excess NADH, the enzyme cycling occurs efficiently and the rate of formation of Thio-NADH is determined by measuring specific change of absorbance at 405nm 5.

Fig 1: Enzyme cycling assay principle 5
Fig 1: Enzyme cycling assay principle (5th Generation Bile Acids)

Want to know more?

Contact us or download the Total Bile Acids Whitepaper.

Related Products

Clinical Chemistry Calibrator

Clinical Chemistry Control

Clinical Chemistry EQA

Reagents Resource Hub


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Future Diagnostics
×
Make an Enquiry - RX series (Product)
×
Make an Enquiry - Quality Control